Brain Health and Disability: Leave No One Behind

The WFN, global regions, and the World Federation of Neurorehabilitation

 

By Tissa Wijeratne, David W. Dodick, Steven L. Lewis, and Wolfgang Grisold

World Brain Day 2023 annually commemorates the foundation of the World Federation of Neurology (WFN) on July 22. The previous World Brain Day themes focused on specific neurological diseases such as Parkinson’s disease, migraine, epilepsy, multiple sclerosis, and many others. We are again partnering with all six regions of the WFN as well as the World Federation for NeuroRehabilitation (WFNR) to unite the world on the disability that results when brain health compromised.

Brain disorders, affecting more than one billion people, are the leading cause of disability-adjusted life years (DALYs). Optimizing brain health, care, and rehabilitation for those with disability from neurological disease is a global priority, requires involvement of policy makers, health care providers, foundations, public health authorities, professional societies, patient advocacy organizations, and the private sector.

The World Health Organization (WHO) identified the following determinants for brain health:

  • Physical health
  • Healthy environments
  • Safety and security
  • Learning and social connections
  • Access to quality services

By addressing these determinants, we can optimize brain health, prevent neurological disease, facilitate early and rapid diagnosis, ensure universal access to care, and thus lower the prevalence and disability associated with most neurological diseases.  For those with progressive, late-stage, and incurable disease, access to palliative care to ensure human dignity at the end of life is an imperative.

The Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022–2031 (IGAP) was initiated by WHO and unanimously adopted at the World Health Assembly on May 27, 2022. [https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_10Add4-en.pdf].

The IGAP provides a comprehensive response to the burden of neurological disorders; the global action plan suggests actions to Member States and national and international partners to close the treatment gap for people with neurological disorders and support quality management of these conditions.

Since the IGAP is also directed to organizations such as the WFN, this is an excellent opportunity to strengthen the collaboration between the WFN and WHO by linking our actions with the principles of the IGAP.

In this year’s World Brain Day | Brain Health and Disability: Leave No One Behind, we intend to highlight five key messages.

Prevention: Brain disabilities can be prevented, treated, and rehabilitated.

Awareness: Global brain health awareness can reduce the burden of brain disorders.

Access: Universal access to care, treatment, rehabilitation, and assistive technology is essential.

Education: Education increases equity for those living with brain disabilities.

Advocacy: Brain health is a human right that applies to everyone, everywhere.

As in the previous World Brain Days, a special logo and material have been produced and will be made widely available for local/regional use by health care professionals, regional and national societies, and all other stakeholders involved in neurological disease advocacy. Before World Brain Day, a template for press mailings will be distributed to help the local organizations. On World Brain Day, a webinar will be launched and, with invited participants from the press, key messaging on brain health and disability will be disseminated.

The ultimate success of World Brain Day depends on your local activities. Please make World Brain Day your own, use all the material we provide, and ask for more if needed. Experience has shown that this international day has created considerable press attention, but local activities and information make the difference.

Please involve patients, caregivers, the public, local, regional, and national policy makers, and patient groups that might be interested in this topic. Please be sure to post your activities on social media to help raise awareness. Join us on World Brain Day as we ensure no one is left behind.

Brain health care faces many global inequalities. Let’s change this together. Let’s leave no one behind.

We eagerly await your reports of your local plans on World Brain Day events so that we can publish them in World Neurology.

Learn more at www.wfneurology.org. •

 

 

Report of the World Stroke Congress 2022 in Singapore

By Stefan Kiechl and Deidre De Silva

The World Stroke Congress (WSC) is the flagship meeting of the World Stroke Organization (WSO). After the exclusively virtual events in 2021 and in 2020 (joint conference with the European Stroke Organization), the WSC 2022 in Singapore was the first international large-scale in-person meeting. With more than 4,400 attendees (approximately half in person and half online) this was the largest WSC ever. It served as an excellent opportunity to discuss latest clinical and research results with colleagues from all over the world. The participants were from 106 countries with highest attendance from colleagues from Australia, China, India, Indonesia, Malaysia, Philippines, Singapore, United Kingdom and the United States. The faculty of 204 invited speakers were well balanced across continents (Asia 34%, South and North America 24%, Europe 25%, Australia and Africa 18 %).

The opening ceremony included a video message from Tedros Adhanom Ghebreyesus, WHO director-general. In the three-and-a-half day program Oct. 26-29, the scientific program committee organized 97 sessions, teaching courses, joint symposia, and plenaries. These covered a broad range of topics, emphasizing the latest research and breakthrough discoveries across the globe, with priorities in acute stroke therapy, primary and secondary prevention, rehabilitation and recovery, cardiac aspects, and intracerebral haemorrhage.

One priority of WSC was the cross-link with partner organizations. The WSO and World Federation of Neurology (WFN) organized a joint symposium on education in stroke. With the conference being held in Asia, this granted the opportunity to collaborate with stroke societies from Asia, such as the Chinese Stroke Association, Asia Pacific Stroke Organization, Association of Southeast Asian Nations Neurological Association, and WHO South-East Asia Regional Office. Stroke support organizations substantially contributed to the WSC 2022, integrated into the main program and also in parallel independent sessions. During the coffee breaks, there was dialogues on non-communicable diseases (NCD).

The WSC 2022 had more than 20 late-breaking trials that were published in top journals like The New England Journal of Medicine and JAMA. One highlight was the first presentation of results of MR CLEAN-LATE. Patients admitted between 6 and 24 hours after stroke (NIH Stroke Scale ≥ 2, occlusion of the internal carotid artery or M1/2 segments of the middle cerebral artery), had a substantial benefit of endovascular stroke therapy. The only patients not considered in these trials were patients with large demarcated infarction (more than third of the territory of the middle cerebral artery) and patients with a collateral score of zero. Patients with indications of endovascular stroke therapy according to DAWN or DEFUSE-3 criteria were also not considered. Other highlights were the meta-analysis of six trials comparing endovascular stroke therapy alone against bridging (combined with intravenous thrombolysis). In this meta-analysis including 2314 patients, endovascular stroke therapy could not prove to be non-inferior to bridging therapy and this is also valid for multiple subgroups. The first phase 3 trial on stem cells in stroke recovery (TREASURE) was negative, a lowering of systolic blood pressure under 120 in successful endovascular stroke therapy has negative impact on the patients’ outcome (ENCHANTED2), and treatment by tenecteplase was non-inferior to alteplase treatment (AcT Study).

The WSC 2022 in Singapore contributed to a better clinical stroke management in the future and facilitated discussion about stroke care in various geographical regions. Hundreds of delegates, local organizers, and stroke advocates joined the annual Walkathon and with “One Voice” raised stroke awareness. The WSC 2023 will be organized in Toronto (Canada) between Oct. 10-12, a few days before the congress of the WFN in Montreal from Oct. 15-18. •

Stefan Kiechl and Deidre De Silva Chaired the Scientific Committee of WSC 2022.

II Latin American Course of Neuroepidemiology

Punta del Este, Maldonado, Uruguay | March 6-10, 2023

 

By Dr. Carlos N. Ketzoian

Participants in the II Latin American Course of Neuroepidemiology, Punta del Este, Maldonado, Uruguay, March 6th to 10th, 2023. In the center, Dr. Daniel Salinas, Minister of Public Health of Uruguay.

Last March, the II Latin American Course of Neuroepidemiology took place in Punta del Este, Maldonado, Uruguay. This course was organized by the neuroepidemiology section of the Institute of Neurology at the University of the Republic in Uruguay, and the Université de Limoges in France, with the endorsement of the World Federation of Neurology (WFN). The course was held at the Eastern Regional University Center (C.U.R.E.) of the University of the Republic, Uruguay.

The I Latin American Course of Neuroepidemiology took place in Panama City, Panama, in April 2018. This II course was initially planned to take place in March 2020. Unfortunately, the COVID pandemic forced the organizers to postpone it until 2023. The structure and the content of these Latin American courses are based on the experience of the Erice’s International Course of Neuroepidemiology. (See World Neurology, posted Feb. 24, 2023. Report on the Ninth International Course of Neuroepidemiology: Methods and Clinical Applications worldneurologyonline.com).

Twenty-one students, five teachers, three coordinators, and two invited speakers participated in five intense and enriching days of learning. Apart from local participants from Uruguay, the remaining students came from different Latin American countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, and Peru. Two participants came from outside of the region (Republic of Armenia).

Profs. Walter Rocca (U.S.), Giancarlo Logroscino (Italy), Pierre-Marie Preux (France), Ruth Ottman (U.S.), Brandon Coombes (U.S.), and Carlos Ketzoian (Uruguay) were part of the teaching team. The course was coordinated by Prof. Carlos Ketzoian (Uruguay), Prof. Regina Alvarenga (Brazil), and Drs. Fabián Gómez Elso and Lucía Castro (Uruguay).

Dr. Sebastián Ameriso from Argentina gave a lecture on the epidemiology of stroke in Argentina and Prof. Abayubá Perna from Uruguay gave a lecture on the genetic epidemiology of limb-girdle muscular dystrophy (LGMD) in Uruguay.

Study design aspects, genetic epidemiology, and statistical methods applied to neuroepidemiology were discussed in the morning. After lunch, the participants analyzed published clinical-epidemiological studies in which the different methodologies presented in the mornings were addressed. Each day, the activities ended with lectures on different topics.

The course activities also included the IV Journée d’Amitié Neurologique Franco-Panamericaine with lectures by Profs. Abayubá Perna (Uruguay), Regina Alvarenga (Brazil), and Pierre Marie Preux (France). The program was endorsed by the French Embassy in Uruguay. A cocktail reception took place after the lectures. The Minister of Public Health of Uruguay, Dr. Daniel Salinas, who is a neurologist, participated in this opening academic and social event. On Friday, March 10, the course closed with a social dinner of traditional “Asado Criollo” (Uruguayan barbecue).

Participants, professors, and coordinators had the opportunity to discuss in-depth different aspects of the clinical-epidemiological methodology for the study of neurological diseases. This full-immersion course format allowed total focus on the subjects, and the participants were not distracted by other activities during the day.  The participants worked together for eight hours a day for five days.

We would like to emphasize that this kind of course corresponds to the objectives defined by the WFN Specialty Group on Neuroepidemiology during the meeting which took place Oct. 30, 2019, at the World Congress of Neurology in Dubai. •

Carlos N. Ketzoian is chair of the WFN Specialty Group on Neuroepidemiology.

Book Review: The Idea of Epilepsy 

A Medical and Social History of Epilepsy in the Modern Era (1860-2020), Simon D. Shorvon, Cambridge University Press

 

By Peter J. Koehler

“Diseases can be considered as acts or invasions by gods, demons, or evil spirits, and treated by the invocation of supposedly supernatural powers. Or they are considered the effects of natural causes and are consequently treated by natural means. In the struggle between magic and the scientific conception, the latter has gradually emerged victorious in the western word. The fight has been long and eventful, and in it epilepsy held one of the key positions. Showing both physical and psychic symptoms, epilepsy more than any other disease was open to interpretation both as a physiological process and as the effect of spiritual influences.” — Owsei Temkin, 1945 

The Falling Sickness

These are the first sentences in Owsei Temkin’s classic book The Falling Sickness. A History of Epilepsy from the Greeks to the Beginnings of Modern Neurology. First published in 1945, a revised edition appeared in 1971, and in 1994 it was published again. The book begins with the “sacred disease” in antiquity, discusses ancient medical science, and touches upon magic, superstition, possession, and lunacy in the Middle Ages. It then passes through the Renaissance period with the “theological debate” on possession and witchcraft, describes theoretical ideas on epilepsy in the great systems (including iatrochemistry, iatromechanics, and animism), discusses the Enlightenment, including pathology and nosology, and then enters into the nineteenth century. Here Temkin dwelt on reflex therapy, described some of the important “Jackson forerunners,” including Richard Bright (1789-1858) and Louis-François Bravais (1801-1843), whose name is sometimes eponymized in the term Bravais-Jacksonian epilepsy. The book ends with an extensive description of the ideas of John Hughlings Jackson (1835-1911) in the second half of the nineteenth century. 

As apparent from the title, the present book by Simon Shorvon, The Idea of Epilepsy. A Medical and Social History of Epilepsy in the Modern Era (1860-2020), begins approximately, where Owsei Temkin (1902-2002) ended, although there is some overlap, in particular with respect to Bénédict Morel (1809-1873), Wilhelm Griesinger (1817-1868), Jules Falret (1824-1902), and Théodore Herpin (1799-1865), who are mentioned in both books.

The Authors

Temkin and Shorvon have quite different backgrounds. Temkin was born in Minsk (in the present Belarus) and received his MD from the University of Leipzig (1927), where he was in contact with well-known medical historians like Henry E. Sigerist (1891-1957) and Karl Sudhoff (1853-1938). Following his MD, he worked at the Leipziger Medizinhistorischen Institut. Both Sigerist and Temkin emigrated to the U.S. (Johns Hopkins University, Baltimore) in 1932 and Temkin remained a medical historian. Some of his important books are Galenism: Rise and Decline of a Medical Philosophy (1973) and Hippocrates in a World of Pagans and Christians. Shorvon, on the other hand, has a background in clinical medicine. He is an emeritus professor of clinical neurology at the University College of London (UCL) Queen Square Institute of Neurology and Hon. Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. In the latter hospital, he specialized in epilepsy. He published books not only on epilepsy, but also on the history of neurology, including ILAE [International League Against Epilepsy] 1909-2009, A Century of History (2009), Physicians at War (2016), 500 Years of the Royal College of Physicians (2018), and the acclaimed Queen Square. A History of the National Hospital and its Institute of Neurology (in cooperation with Alastair Compston; 2019). 

The Idea of Epilepsy

These two books by Temkin and Shorvon complete a fantastic review of the history of epilepsy. Whereas Temkin’s 1994 edition on the early history of epilepsy comprised 488 pages, Shorvon’s new book on the 1860-2020 period has as many as 750 pages. The latter book contains a wealth of information about the latest 160 years, in which knowledge of epilepsy increased tremendously. In the introduction, the author appropriately uses the metaphor of a ship named “Epilepsy” sailing through the long twentieth century. Very appropriately, he is aware that the medical and scientific aspects of the history of epilepsy are not the only that need to receive attention. A disease such as epilepsy in particular has many important aspects that deserve to be addressed. Therefore, the author chose to examine the history of epilepsy from four perspectives, not only including the medical and scientific, but also the societal and personal perspective. Furthermore, he tried not just to answer the question, “What happened?” but also “why it happened,” the latter of course being much more difficult and even “hazardous.”

The reason why he chose to begin in 1860 is that he considered this the period of the first modern conceptions of epilepsy. Indeed, the mid-nineteenth century was the period in which medicine definitely became based upon science. This was related to August Comte’s (1798-1857) positivistic philosophy. Scientific knowledge was obtained by representing results in measure and number. Claude Bernard (1813-1878) and Rudolf Virchow (1821-1902) were important proponents of the scientific method in medicine. Their respective books Introduction à l’étude de la médecine expérimentale (CB 1865) and Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre (RV 1858) may be considered milestones of the scientific method in medicine.

Epilepsy and Psychiatry

The 160 years that are discussed in Shorvon’s book are divided into five periods: 

1. 1860-1914 (“The birth of modern epilepsy”)

2. 1914-1945 (“Epilepsy in the age of catastrophe”)

3. 1945-1970 (“Epilepsy and the new world order”)

4. 1970-1995 (“Epilepsy in a globalized world”)

5. 1995-2020 (“The epilepsy floods are too recent”) 

Cesare Lombroso (courtesy Wellcome Collection)

In each period, the four mentioned perspectives pass in review. The relationship between epilepsy and psychiatry in the first mentioned period is intriguing.  The author mentions Cesare Lombroso’s (1835-1909) and his famous book L’uomo delinquente (1876), in which the author focused on the link between epilepsy and crime. Furthermore, Shorvon stated that “it was in the context of the study of mental symptoms in epilepsy that the theory of dégénérescence (degeneration) was proposed, again by Morel,” referring to his 1857 Traité des dégénérescences physiques, intellectuelles et morales de l’espèce humaine et des causes qui produisent ces variétés maladives [A treatise on the physical, intellectual and moral degenerations of the human species and the causes that produce these morbid varieties]. Indeed, Morel published on the relationship between epilepsy and his degeneration concept, but it was in a number of articles in the Gazette hebdomadaire that he described his concept of épilepsie larvée (masked epilepsy).1 The degeneration concept started in psychiatry with proponents such as Morel and Valentin Magnan (1835-1916). 

“Insanity gradually came to be considered a brain condition and a product of degeneration rather than a psychological disorder. … A ‘taint’ or sickly deviation from the norm initially caused by a pathogenic environment, poor nutrition, or alcoholic abuse, and subsequently transmitted in the Lamarckian manner through heredity, becoming progressively more severe with each generation until the family line became sterile and, finally, extinct”.2  

Later in his career (1880s), Jean-Martin Charcot (1825-1893) believed that heredity also played an important role in neurological conditions and thought these afflictions could be interrelated by means of inheritance.3 It is of interest to mention that the degeneration concept had a tremendous impact on the fin de siècle society, including its literature. In one of his lectures, he said, “Gentlemen, I will now present for clinical examination, two unfortunate creatures who deserve compassion. One may say that one as well as the other have been touched by the antique fatality that nowadays has been substituted by hereditary fatality.” 

Among other fictional characters, Shorvon provides the example of Emile Zola’s (1840-1902) La Bête Humaine, in which a character carried “the physical stigmata of epilepsy.” In fact, the concept of degeneration can be found in the whole 20-volumes Rougon-Macquart series. It should be realized that the fin de siècle was characterized by cultural malaise partly caused by these ideas of degeneration, but also by the uncertainty and anxiety of approaching the end of a century. Fear for decay and disaster reigned. The notion of degeneration was perceived by the lay public as well as by artists.3,4  

An interesting section is dedicated to “psychoanalytic theory and epilepsy.” The author tells us that psychoanalysis provided a novel explanation of epilepsy. “As its theories matured, the view grew that essential epilepsy was the result of inhibited psychological development caused by inherited traits which prevented normal psychic development and were manifest both by epileptic seizure and abnormalities of personality” (p. 166). Indeed, it is a general phenomenon that new ideas and therapies in medicine initially have a much broader area of indications, to become much narrower or disappearing after some time. As for neurology, another affliction in which this happened, i.e. psychotherapy, was dystonia.5 A few other issues of interest discussed here are the idea of the epileptic personality and the psychiatric effects of temporal lobe epilepsy.

Stigma

Fjodor Dostoievsky (public domain)

Shorvon dedicates a paragraph on “eugenics and epilepsy.” Indeed, it did not escape involuntary sterilization in some countries, not just in Nazi Germany in the 1930s and 1940s. Furthermore, it is fascinating to read about the early pathophysiological ideas, including the reflex theory, the idea of autointoxication, and the Bacillus epilepticus (1916). And, of course, he mentions the asylums and colonies established for epileptic patients, in a period when drugs where less successful than today. The stigma of having epilepsy and the patient’s experience are discussed in detail. Several celebrities are mentioned in the context, like Queen Victoria’s epileptic son Prince Leopold of Albany and the Russian writer Fjodor Dostoievsky (1821-1881).  He not only suffered from epilepsy himself, but also wrote about it in several of his novels. Although it is not certain, he may have been treated by the optimistic Herpin. He was one of the doctors Dostoevsky listed on his visa application of 1863, the year in which he traveled abroad for the official purpose of consulting the greatest European authorities on epilepsy, including Moritz Romberg (1795-1873), Armand Trousseau (1801-1867), and Herpin. It is likely Dostoevsky had Herpin in mind when writing The Idiot.6,7

The importance of the introduction of the EEG (1929) and the early twentieth-century drugs are all mentioned in the book, including those that have disappeared later. A paragraph is dedicated to the role of the pharmaceutical industries through history. A table on the chemical and physiological basis of neurotransmission between 1900 and 1970 is also provided. Several “new” pictures can be seen in the book, like the one of Horsley in the operating theatre with Samuel A. Kinnier Wilson (1878-1937) and Emil T. Kocher (1841-1917), c. 1906.

Why not Brown-Séquard?

Charles-Edouard Brown-Séquard (public domain)

Although it is impractical to include all historical texts dealing with epilepsy, I would have expected a more extensive discussion of Charles-Edouard Brown-Séquard (1817-1894) and his views on epilepsy. Having written my dissertation on Brown-Séquard’s localization concept, I am of course biased, but in the present book only a sentence and two footnotes are dedicated to him. I was surprised all the more so, since he was in fact the predecessor of Shorvon himself. After all, considered an expert in epilepsy, Brown-Séquard was the one of the founder-physicians to be appointed at the National Hospital for the Paralyzed and Epileptic (1859), where he became a teacher of Hughlings Jackson. Jackson’s colleague and life-long friend Jonathan Hutchinson (1828-1913) wrote: “My friend fell, soon after he joined me in London life, under the influence of Dr. Brown-Sequard, who told him strongly that it was foolish to waste his efforts in wide observation of disease in general, and that if he wished to attain anything he must keep to the nervous system.” 

John Hughlings Jackson (public domain)

Furthermore, it was Brown-Sequard who told Hughlings Jackson that a vacancy for the post of assistant physician would be advertised. He indeed applied and was appointed on in May 1862.8 Brown-Séquard was among the first to prescribe bromide for epilepsy9, pp. 102-14 and between 1850 and 1872 published many articles as well as a book on epilepsy.10 Furthermore, he had found an experimental model for what he called spinal epilepsy, which became also known as Brown-Séquard’s epilepsy.11,12 

Finally, from today’s perspective, it is doubtful whether it was truly an epileptic phenomenon, as it was related to the ankle clonus by Wilhelm Heinrich Erb (1840-1921) and Charcot. However, it aroused interest for several decades.9, pp.183-93 Perhaps Shorvon did not discuss him, because it was partly before 1860, although the same is true for Herpin and his book Du pronostic et du traitement curatif de l’épilepsie [Prognosis and treatment of epilepsy] that was published in 1852. Or perhaps it is due to the fact the Brown-Séquard’s concept was finally rejected as epilepsy in the sense of having its origin in cortical cells. 

Neurosis 

I may be in error, but sometimes I wondered whether the author sufficiently distinguished between the old neurosis concept and the modern post-Freudian term (psycho)neurosis. On page 58, we find that “epilepsy was still viewed generally as a mental disorder in the period under consideration, and treated largely in the arena of psychiatry.” It is of importance to understand the history of the term neurosis, as its meaning underwent an important evolution, which is related to neurology as well as psychiatry.13 William Cullen (1710 – 1790) of Edinburgh coined the term neurosis, applying it to what his Edinburgh colleague and predecessor Robert Whytt (1714-1766) called nervous diseases. This functional orientation of neurosis remained during almost the whole nineteenth century,14 though the category of neuroses became smaller as more diseases were found to have a neuropathologic substrate, beginning with general paralysis of the insane in the 1820s. In the 1880s, for example, William Gowers (1845-1915) mentioned the following functional disorders: chorea, paralysis agitans, tremor, tetanus, tetany, occupation neurosis, etc.15 

During the twentieth century, even more of these neuroses were found to have an organic basis. The present sense of the term neurosis dates from the period of dynamic psychiatry in the beginning of the twentieth century and may be called psychoneurosis, e.g. anxiety neurosis, obsessional neurosis, etc. Interestingly, neurologists have treated these patients with “nervous disorders” or “nerves” for a long period.16,17 Therefore, I am not sure whether the old concept of neurosis can be equated with mental disorder, as it was associated rather with the fact that no pathological substrate was found. As for the “arena of psychiatry,” we have to realize that in many countries, particularly the German-speaking and those adopting the German system, neurology was included in psychiatry for several decades.

Criticism

The author is to be lauded that he tried to write not only for physicians, neurologists in particular, but wished to write also for the “informed public.” Therefore, he included a glossary of technical terms. Furthermore, he tried to avoid making it a book on “Great Men” and find a balanced choice with respect to the level of details. Indeed, the book is not based on important physicians in the field of epilepsy.

One shortcoming, which the author mentions himself in the introduction, is that there is a bias of language. He examined texts mainly in English. That does not mean, by the way, that he does not mention French and German researchers, but I suppose he often will have used existing translations for that purpose. And indeed, he does describe important players in the field of epilepsy from other countries than England and the United States. 

Perhaps among the minor criticisms the fact could be mentioned that the author often refers to the Pitié-Salpêtrière hospital. The “new” Pitié hospital (where Joseph Babinski [1857-1932] worked since 1895), however, was built near the Salpêtrière only in 1911 and the merging of the two took place in 1964. And Paul Broca of course did not show that “the expression of speech was localized in the left frontal gyrus in 1871” (p. 74). He localized it in the frontal convolution in 1861 and only in the 1863-5 period, he realized that most cases were in the left hemisphere. Furthermore, we read “The first systematic studies of anatomical-topographical analysis using electrical stimulation were by Fritsch and Hitzig.” Indeed, they found positive results of their cortical stimulation experiments in 1870, however, in the early nineteenth century, many other experimenters preceded them, without seeing any limb movements. As medical historian Michael Hagner wrote: “These results were repeatedly reproduced by distinguished physiologists like François Magendie, François-Achille Longet, Carlo Matteucci, Julius Budge, and Moriz Schiff, and, moreover, these physiologists failed in attempts to evoke muscle twitching through cortical stimulation, whether with electrical stimulation, cauterization, or compression.” And I am not sure whether the experiments by Fritsch and Hitzig were really more systematic than the previous. Continuing in Hagner’s article “Several divergent paths led to the emergence of this stimulus experiment. They led through realms of clinical medicine that had nothing to do with localized diseases of the brain, through therapeutic practices, and not least through alternate experiments and theories that arose from entirely other lines of questioning.”19 

The End of Epilepsy?

Perhaps, in a book on the history of a certain subject, one would not expect to continue the story up to the present. On the other hand, in this book on epilepsy, the story is told by an experienced epileptologist, who was part of that story for 40 years. Therefore, it is obvious that he provides his own opinion in the Epilogue, where he writes: “Even if fascinating in its own right, any history of epilepsy can be useful only if it helps make sense of the reality of epilepsy today” (p. 585), although he realizes and explains, in the accompanying footnote, that history can only stimulate new thinking about the present. 

It would be a mistake to think that events in history and today are homologous, referring to philosopher Hannah Arendt (1906-1975). Using the appropriate metaphor of epilepsy as ideas, “like leaves, seeming strong and vigorous at one time, wither and fall with a transience and an insignificance unthinkable at the time,” the author states that the tree also has permanent structures like branches and a trunk that grow. Indeed, he also attempted to make up an “epilepsy balance sheet” with theories and practices that have improved or harmed epilepsy through the long twentieth century. In the accompanying text, he contemplates about what happened and what deserves criticism in the various fields, including the political and economic context, legislation and social attitude, delivery of epilepsy healthcare, pharmaceutical attitude, etc. An interesting paragraph in the Epilogue is “The harm caused by medicine.”

In the introduction and Epilogue again, Shorvon tries to answer the question, whether “Epilepsy really exists” today, or stated differently “The end of epilepsy?” Hereby he follows up on Temkin, who titled the final section of his book “The end of the falling sickness.” May it still be considered a disease, as in the past, or did the progress in knowledge result in disappearance of the disease, now only being a symptom (pp. 7 and 623)? 

From the medical and scientific perspective there are, Shorvon believes, numerous arguments to drop the term epilepsy as a disease and continue to use epileptic seizure as a clinical manifestation or symptom. Referring to the German neurologist/medical historian and émigré Walther Riese (1890-1976), he realized that epilepsy is not just a medical and scientific concept, but also an idea laden with social and personal signification. Thinking of the disadvantages of the stigma, the author concludes: “Given that it does not exist as a disease, that it carries with it dark and deeply engrained archetypal memories of heredity, mental disease and impairment, and that it confers prejudice and social exclusion, I think the removal of the term ‘epilepsy’ from public discourse is at least worthy of debate. My personal opinion is that the gain might well outweigh the drawbacks. Much as Temkin had hoped, perhaps at this juncture, the end of epilepsy is possible to envisage. This would indeed be a goal worth achieving” (p. 629).

In conclusion, this book is a rich source of interesting aspects of the history of epilepsy in the past 160 years. It is recommended for physicians, in particular neurologists, and those non-medically trained persons interested in epilepsy and its history. •

 

References:

  1. Lund M. On Morel’s ‘épilepsie larvée: the first Danish epileptologist Frederik Hallager’s opposition in 1884 against Morel’s psychical epileptic equivalents. J Hist Neurosci. 1996;5:241-53.
  2. Goldstein J. Psychiatry. In: Bynum WF, Porter R, eds. Companion encyclopedia of the history of Medicine. London, Routledge, 1997.
  3. Koehler P. About medicine and the arts. Charcot and French literature at the fin-de-siècle. J Hist Neurosci. 2001;10:27-40.
  4. Koehler PJ. Charcot, la salpêtrière, and hysteria as represented in European literature. Prog Brain Res. 2013;206:93-122.
  5. Munts AG, Koehler PJ. How psychogenic is dystonia? Views from past to present. Brain. 2010;133:1552-64
  6. Johnson BR. Diagnosing Prince Myshkin. The Slavic and East European Journal 2012;56:377-93.
  7. Rice JL. Dostoevky’s Medical History: Diagnosis and Dialectic. The Russian Review. 1983;42:131-61.
  8. Critchley M, Critchley EA. John Hughlings Jackson. Father of Englsih Neurology. New York, Oxford University Press, 1998, pp. 37-8.
  9. Aminoff MJ. Brown-Séquard. An Improbable Genius Who Transformed Medicine. New York, Oxford University Press, 2011.
  10. Brown-Séquard CE. Researches on epilepsy. Its artificial production in animals and its etiology, nature and treatment in man. Boston: Clapp, 1857
  11. Koehler PJ. Brown-Séquard’s spinal epilepsy. Med Hist. 1994;38:189-203.
  12. Koehler PJ. Het localisatieconcept in de neurologie van Brown-Séquard. Amsterdam, Rodopi, 1989, pp. 59-63.
  13. López Piñero JM. Historical origins of the concept of neurosis. Cambridge: University Press, 1983.
  14. Bynum WF. The nervous patient in eighteenth- and nineteenth-century Britain: the psychiatric origins of British neurology. In: Bynum WF, Porter R, Shepherd M, editors. The anatomy of madness. Vol.1, ,  London, Tavistock, 1985, pp.89-102.
  15. Gowers WR. A manual of diseases of the nervous system. 2 vols. London, Churchill, 1886-1888.
  16. Shorter E. A history of psychiatry. New York, Wiley, 1997, pp.113-144.
  17. Koehler PJ. Development of neurology as a specialty in Europe. In: Education Program Syllabus: History of neurology, American Academy of Neurology, 2007, pp. 72-89
  18. Philippon J, Poirier J. Joseph Babinski : A Biography. New York, Oxford University Press, 2009, pp. 151-66.
  19. Hagner M. The electrical excitability of the brain: toward the emergence of an experiment. J Hist Neurosci. 2012;21:237-49.

An Important Year for Neurology

By Wolfgang Grisold

Wolfgang Grisold

Wolfgang Grisold

Welcome to this first issue of World Neurology in 2023. This newsletter is an important information instrument for the WFN, and each issue reaches at least 15,000 readers. I encourage members to use this instrument and submit news and important aspects regarding neurology in your region.

The year 2023 will be an important year for neurology, and for the WFN. The year will bring face-to-face meetings and personal encounters and will reveal how stable and useful our newly developed communication tools are. My prediction is that our communication has dramatically increased during the COVID crisis, and several aspects of electronic communication will remain. The issue of traveling is increasingly also discussed with environmental considerations, and the carbon footprint is increasingly important. The numerous worldwide crises have also complicated traveling and visa issues are gaining importance.

2023 will be the year of a World Congress of Neurology (WCN), this time in Montreal Canada, and follows the WFN concept of traveling with meetings from region to region. Canada is a region rich with research, concepts, education, and also very advanced neurology services. We are glad and honored that the Canadian Neurological Society is holding this congress with us, and we believe world congresses always have a positive effect in the regions to promote the awareness of neurology.

We are looking forward to the global participation and hope many delegates from all parts the Americas (as the hosting region) will be able to attend. We are aware of visa issues, and we appreciate that our hosts are doing the utmost to make the entry for members of societies from other global regions possible.

At the WCN, we will also see three elections: a new treasurer replacing Prof. Stark, a new trustee replacing Prof. Freedman, and the decision on the congress site 2027 in the Arab/African region. Both Prof. Stark and Prof. Freedman have served two terms in the WFN, and we are grateful for their continuous efforts.

For the WCN, from the practical point, the congress committees have created an interesting program with selected plenary lectures, scientific, and educational topics. We are glad to see that almost all participants from the global neurologic alliance are involved in the program, and the distribution of speakers includes more regional speakers than before.

Free lectures and guided poster sessions are waiting for your participation. Please look at the WFN and WCN congress site for the abstract submission. Again, please also check your travel possibilities and your visa requirements.

With the help of our professional congress organizer Kenes, we will add more interactivity in the congress, and we also will have several joint sessions with the WHO and members of the Global Neurology Alliance, such as the World Psychiatric Association and the World Federation of Neurosurgery, among others. The WFN educational subcommittee of “young neurologists” will organize two important sessions.

A patient day will be organized with the Canadian Neurologic Society (CNS), and the WFN is aiming to establish a global patient platform.

We are aware that traveling might not be easy for several reasons, yet there is need to make this congress available worldwide to all member societies. The WCN 2023 will have a virtual component, which will allow access to the program at low costs in low and low-middle income countries. Participation and dissemination of the developments in neurology are the main aims of the WCN. There will be reduced fees for low and low-middle income countries, and as always also congress bursaries will be available.

The WCN is one important aspect of the WFN’s activities, but there are others

Education: The work with educational activities progresses, and a department visit program for Asian candidates is being established by the Indian Academy of Neurology and will be announced soon.

We will continue the educational days, with the WFN day (which will be in December and devoted to neuropathies) and the joint (with the International Headache Society) IHS Headache Day in May. As a new addition, we are planning an educational day in cooperation with the Asian Oceanian Academy of Neurology (AOAN).

WHO and UN-ECOSOC: The cooperation with the WHO continues and, as in the last year, brain health and the implementation of IGAP are major tasks among others. This year’s World Brain Day (WBD) will be organized by regions in cooperation with the WFNR (World Federation of Neurorehabilitation) and is dedicated to “Brain health and disability.” Please follow WBD on the website, and we hope that all member societies will be able to contribute locally.

The global neurology alliance (GNA), consisting of world societies, specialist societies, regions, and the WFN specialty groups, will have a meeting at the WCN in Montreal. It is a powerful network, and the WFN will continue its efforts to cooperate with global societies and specialist societies.

Prof. Steven Lewis and I met with the president and other dignitaries of the World Psychiatric Association in Vienna in January (photo), to discuss future cooperations in regard to brain health and mental health.

The WFN wishes a successful and prosperous year in your region, and globally for neurology. •

Late AAN President Sacco Strengthened International Relationships

By Orly Avitzur, MD, MBA, FAAN

Ralph L. Sacco, MD, MS, FAHA, FAAN

The untimely passing of Ralph L. Sacco, MD, MS, FAHA, FAAN, has saddened not only his colleagues at the American Academy of Neurology, where he served as president from 2017 to 2019, but the wider world of neurology as well. Sacco succumbed from a brain tumor on Jan. 17, 2023, at his home in New York with his family by his side.

During Sacco’s term as AAN president, its international membership climbed from 7,000 to 8,000—a record representing 21% of total membership and 141 countries. The number of International Scholarships, enabling young physician recipients from around the world to receive a $2,500 scholarship to the AAN Annual Meeting, doubled from 15 to 30 and set the stage for an increase to 35 for the 2020 Annual Meeting.

Sacco also strongly supported the AAN International Subcommittee, charged with promoting and developing strategies focusing on outreach and education for neurology in resource-limited countries or regions of the world to facilitate better care for patients with neurologic disease. The subcommittee continues to focus on meeting the needs of our global members, including improved access to membership benefits in low and low-middle income countries and supporting scholarships to the AAN Annual Meeting.

The opportunity to represent American neurology and the AAN to the international community delighted Sacco. He and Academy leadership attended the World Federation of Neurology’s 23rd World Congress of Neurology in September 2017 in Kyoto, Japan. Cohosted by the Japanese Society of Neurology and Asian and Oceanian Association of Neurology, the event’s theme was “Defining the Future of Neurology,” a topic of great interest to Sacco. He was the regional representative and the AAN’s delegate to the general assembly meeting, and chaired the North American Regional Symposium, which focused on prevention and treating common neurologic conditions. He spoke on treatment and prevention of stroke.

In December 2018, he and AAN CEO Catherine M. Rydell, CAE, traveled to Israel, where he gave presentations at the Israel Neurological Association (INA) annual meeting about the AAN and stroke, his specialty, and shared the stage with Dr. David Tanne, president of the INA; Natan Bornstein, past president of the INA; and Dr. Martin Dichgans, president of the European Stroke Organization. He also met with Israeli dignitaries, including the Israeli Minister of Health Rabbi Yaakov Litzman and president of the Israeli Medical Association Prof. Zion Hagay. He enjoyed touring Jerusalem’s Old City, Tel Aviv, and Jaffa.

“We traveled together to Santiago, Chile; Kyoto, Japan; Lisbon, Portugal; Tel Aviv, Israel; and Amsterdam, the Netherlands; among others,” said Rydell. “Ralph and I always felt so welcomed at each and every international society gathering including those hosted by the World Federation of Neurology, the European Academy of Neurology, and other international conferences and meetings that were so honored to have Ralph there to lecture and advise. It was a joy to see him interact with professionals who admired his intellect, his welcoming demeanor, and his one-of-a-kind Sacco smile.”

Sacco attended annual meetings of the Mexican Academy of Neurology, most recently in November 2021 as chair of the AAN Academic Neurology Committee, where he shared how the AAN is helping academic neurology in the U.S. meet a variety of challenges from revenue and funding issues to research and student recruitment.

In June 2019, Sacco was interviewed by AAN staff about the successes, challenges, and opportunities during his recently concluded term as president. He spoke with great joy and at length about the AAN’s relationship with the international neurology community and its leading organizations.

“Although we are the American Academy of Neurology, we do have an international mission, and that’s been important, and prior presidents have really helped push that. We recognize that we only have so much in terms of revenue and we probably can’t especially alone solve the problems, for example, in places like Africa, where there is just a totally insufficient number of neurologists to meet the demands.

“So, a lot of the things that we do to meet the demands and to help with international mission include collaborations. Part of it was working with important other organizations—the World Federation of Neurology, that really does have a truly global mission. We have developed a very close working relationship with the leaders of the World Federation of Neurology, contributing financially and contributing our ideas and thoughts to help with their mission. Working with the European Academy of Neurology, for example, in the course that’s provided particularly for training young members in African nations. We have a great relationship to the Mexican Academy of Neurology. I happened to go to their meetings and developed a close relationship with the Mexican Academy of Neurology.

“Because of some personal relationships, I got to go to the Pan Arab United Neurological Societies’ meeting in Jordan, and that was great to actually work with that group. Also, we were invited to go for the first time to the Israeli Neurological Association. Through this collaborative relationship-building with these other organizations, I think the Academy can help meet the needs of its international mission.

“We also further developed the International Subcommittee under Jerome Chin [Jerome H. Chin, MD, PhD, MPH, FAAN] which is a subcommittee of our Membership Engagement Committee. We expanded the number of international scholarships. When we give out money to bring young people from other nations to come to our Annual Meeting, that has an incredible impact on their career. I can’t tell you the number of people out there who say that that was life-changing for them when they attended the Academy of Neurology. So that was helpful to expand the number.

“We provide Continuum® free to many countries where they’re underserved or under-financed, and that has had a major impact on getting them exposed to a high-quality information to improve their careers. So, there are many, many ways that we work both with other organizations and within the Academy to expand our international mission.”

Sacco was the chairman of neurology; Olemberg Family Chair in Neurological Disorders; Miller Professor of Neurology Public Health Sciences, Human Genetics, and Neurosurgery; executive director of the Evelyn McKnight Brain Institute; senior associate dean for Clinical and Translational Science, University of Miami, Miller School of Medicine; and chief of the neurology service at Jackson Memorial Hospital.

A graduate of Cornell University and a cum laude graduate of Boston University School of Medicine, Sacco received a master’s in epidemiology from Columbia University, School of Public Health. He completed his neurology residency training and postdoctoral training in stroke and epidemiology at Columbia Presbyterian in New York. He was previously professor of neurology, chief of Stroke and Critical Care Division, and associate chairman at Columbia University before taking his most recent position in 2007.

Sacco was an international expert in stroke epidemiology and health disparities. He was the founding principal investigator of the Northern Manhattan Study, the Florida Puerto Rico Collaboration to Reduce Stroke Disparities, and the Miami Clinical Translational Science Institute, as well as co-investigator of multiple other NIH grants. Sacco published extensively with over 1,000 peer-reviewed articles (h-index 109) in the areas of stroke prevention, treatment, epidemiology, risk factors, vascular cognitive impairment, human genetics, and outcomes and has been listed as a Web of Science Highly Cited Researcher since 2017.

He was the recipient of numerous awards, including the AAN Wartenberg Lecture, AHA Feinberg Award of Excellence in Clinical Stroke, the WSO Global Stroke Leadership Award, AHA Gold Heart Award, the NINDS Javits Award in neuroscience, and numerous named lectures.

Sacco was a fellow of both the Stroke and Epidemiology Councils of the American Heart Association, a fellow of the ANA, and an elected member of the Association of American Physicians and National Academy of Medicine. He was the first neurologist to serve as the president of the American Heart Association from 2010 to 2011.

Visit AAN.com/Sacco to learn more about this giant of neurology and to leave memories. •

First Pan-European University Course on Clinical Autonomic Neuroscience

The course is provided at the Danube University and supported by the European Federation of Autonomic Societies.

By Walter Struhal

Walter Struhal

The autonomic nervous system (ANS) regulates the synergistic action of all visceral organs and homeodynamic processes. ANS is involved in the course of many neurologic and systemic diseases. Recently, ANS involvement including postural tachycardia syndrome was identified to play a significant role in cases with post-COVID condition.

ANS diseases may cause various dysfunctions, for example, transient loss of consciousness, sweating disorders, digestion, and urinary and sexual function. Autonomic involvement may be generalized, or focal. It may involve central, and/or peripheral ANS structures. The transformation of this appealingly complex pathophysiology into a clinical picture helps to explain the patient’s symptoms, define the syndrome and initiate treatment. A number of therapies are well-investigated but “off-label.” Diligent transformation of literature research into state-of-the-art therapeutic strategies is therefore an important competence of a clinical autonomic neuroscientist.

European Program of Clinical Autonomic Neuroscience

The European Federation of Autonomic Societies (EFAS), together with the Danube University Krems, and the Karl Landsteiner University of Health Sciences have initiated the first Pan-European University Course to study techniques on bedside and lab investigations of ANS disorders and common strategies of therapeutic management. This academic postgraduate course takes one year and will be completed with a university diploma.

This program is open to medical doctors in training and specialists of all disciplines. This program is open for registration. Register now. •

From the Editors

By Steven L. Lewis, MD, Editor, and Walter Struhal, MD, Co-Editor

Steven L. Lewis, MD, Walter Struhal, MD

We’d like to welcome all readers to the February 2023 issue of World Neurology.

This issue begins with the President’s Column, where World Federation of Neurology (WFN) President Dr. Wolfgang Grisold describes the many international activities being planned by the WFN this year, including the work done with WHO and the UN, World Brain Day 2023, and the exciting plans for the World Congress of Neurology in Montreal in October.

Dr. Orly Avitzur, current president of the American Academy of Neurology, provides a heartfelt memorial piece dedicated to the late AAN President Ralph Sacco, who passed away last month and who touched the lives of so many neurologists and patients and whose dedication to international relationships will be one of many long-lasting legacies of his countless accomplishments.

This issue also features an important notice by the WFN Nominating Committee with a call for nominations for the positions of WFN Treasurer and WFN Elected Trustee. In another announcement, Dr. Struhal describes the first pan-European university course on clinical autonomic neuroscience at Danube University, supported by the European Federation of Autonomic Societies. Dr. Carlos N. Ketzoian then reports on the highly successful Ninth International Course of Neuroepidemiology that took place in Erice, Italy, this past November.

In this issue’s History article, Dr. Peter J. Koehler provides an informative and remarkably thorough overview of the historical dignitaries memorialized by the many named lectures at the World Congress of Neurology (WCN). Dr. Augustina Charway-Felli and Dr. Amadou Gallo Diop report on the outcome of the biennial Francophone contest held at the headquarters of the African and Malagasy Council for Higher Education, and the significance of this event with regard to growing the African neurological and scientific workforce with these successful candidates.

Dr. Vladimir Hachinski, a past president of the WFN, provides an overview of the importance of dementia prevention in global efforts to reduce the impact of this highly prevalent entity, which is increasing in overall incidence worldwide.

Four articles represent thoughtful and well-illustrated reminiscences by four young neurologists from sub-Saharan Africa who participated in the WFN Department Visit Programs in Austria (Graz, Innsbruck, and Salzburg) and Germany (Leipzig). We would like to add our deep thank you to the neurologic societies in Austria and Germany for their wonderful support, hard work, and attentiveness in making these observerships a success, increasing the exposure of high-level neurologic infrastructure to these young neurologists to inform and enhance their clinical practices.

Dr. Tissa Wijeratne and Dr. David Dodick (Co-Chairs of World Brain Day) and Dr. Lewis and Wolfgang Grisold next report on the plans for this year’s World Brain Day 2023, which will be dedicated to “Brain Health and Disability. It will include collaborations between the WFN, our global regions, national neurologic societies, and the World Federation of Neurorehabilitation.

Finally, Dr. Richard Stark, WFN Treasurer and past chair of the WCN Tournament Committee, provides historical background about the Tournament of Minds at the World Congresses of Neurology (WCNs), with an announcement about this year’s Tournament of Minds. The tournament will be held at this year’s WCN in Montreal in October, welcoming and pitting department teams from around the world to compete in this exciting and well-loved component of the WCN.

In closing, we want to thank all readers for their interest in and attention to World Neurology. Please don’t forget to sign up for your free subscriptions online at worldneurologyonline.com. We sincerely hope everyone is marking their calendars, making plans to attend, and submitting their abstracts for the WCN in Montreal in October 2023. We look forward to seeing so many neurologists from around the world participate in this remarkable event. •

Report on the Ninth International Course of Neuroepidemiology: Methods and Clinical Applications

By Dr. Carlos N. Ketzoian

Participants in the Ninth International Course of Neuroepidemiology: Methods and Clinical Applications.

Last November, the ninth edition of the International Course of Neuroepidemiology:  Methods and Clinical Applications took place in Erice, Sicily, Italy, with the WFN’s endorsement.

An historical first course of neuroepidemiology was held in San Miniato, Pisa, Italy, in 1981, and was organized by Prof. Bruce Schoenberg.

Prof. Schoenberg passed away six years later. He laid the foundation for the development of neuroepidemiological research in different continents as a legacy. The activities that he promoted were oriented both to support researchers and to prioritize the training of human resources in this area of knowledge.

Almost 20 years after these historical events, Professors Walter Rocca (Mayo Clinic, Minnesota, U.S.) and Giovanni Savattieri (University of Palermo, Italy) resumed the training activities pioneered by Prof. Schoenberg. Starting in 2000, the nine offerings of the “International Course in Neuroepidemiology: Principles and Clinical Applications” in Erice, have become an essential point of reference for those of us who are interested in the subject.

Over the years, the structure, thematic content, and methodology have evolved in order to adapt to the new needs of a changing international public and to the new methodological developments.

Flyer of the Ninth International Course of Neuroepidemiology: Methods and Clinical applications.

Professors Paolo Ragonese and Marco D’Amelio from the University of Palermo, Italy, who participated as students in the 2000 course, are the current coordinators. The course has a Scientific Committee and a Teaching Team, including more than 15 worldwide leaders in neuroepidemiology and other related sciences. It is a high-level full-immersion course where participants share five days of training, exchange experiences, and establish professional collaborations that go beyond the course.

Forty-six students from five continents participated in this Ninth International Course of Neuroepidemiology: Methods and Clinical Applications” in Erice 2022. Methodological aspects of neuroepidemiology were discussed in the morning, and applications of the methods to the study of specific neurological diseases were presented in the afternoon (epilepsy, dementia, Parkinson’s disease, stroke, multiple sclerosis, neurological manifestations of COVID, among others). General concepts of genetic epidemiology and of applied statistics complemented the epidemiologic methods essential for neuroepidemiology.

The infrastructure of the Ettore Majorana Foundation Centre for Scientific Culture provided a unique framework to achieve the aims. As we climbed the winding road that took us up Mount San Giulano to Erice, a medieval city, the air became fresh and the landscape splendid. Cloistered for a week in this inspiring environment, we felt invited to expand our knowledge as if we were part of a renaissance movement in neuroepidemiology.

The current coordinators, Professors Paolo Ragonese and Marco D’Amelio, organized a special tribute to Professors Walter Rocca and Giovanni Savattieri in recognition for their work in establishing the Erice courses and for their commitment to the development and the diffusion of neuroepidemiology. The Erice courses have become one of the points of reference for the training of young neurologists in clinical and epidemiological research. •

Dr. Carlos N. Ketzoian is chairman of the Specialty Group on Neuroepidemiology of the World Federation of Neurology.

Reference:

  1. Walter A. Rocca, Paolo Ragonese, Marco D’Amelio, Giovanni Savettieri (2022) Teaching Research Methods to Young Neurologists: The Erice International Courses. J Mov Disord 2022;15(3):227-231

Nominating Committee Announcement 2023

On behalf of the World Federation of Neurology, the Nominating Committee invites nominations for the positions of Treasurer (four-year term) and Elected Trustee (three-year term).

Treasurer to take office from Jan. 1, 2024. (Position vacated by Dr. Richard Stark, who is not eligible for re-election.) Having previous similar experience as a treasurer would be an advantage.

One Elected Trustee to take office immediately following the election. (Position vacated by Dr. Morris Freedman, not eligible for re-election.) A nominee must be a member of an eligible WFN member society, should have a national and international reputation, have made contributions to regional and global neurology, and be committed to the WFN.

A WFN Member Society must submit the name(s) of the candidate(s), together with a statement signed by the candidate of confirmation of their willingness to stand for election, provide a brief curriculum vitae (a single type-written page) and letter of support from the Member Society. This has a deadline of April 3, 2023.

Nominations made after this deadline are possible. In addition to the criteria above, the candidate must also be supported with signatures from a minimum of five WFN Member Society Delegates, and all documents must be received by the London office 30 days prior to the Annual General Meeting.

Please address the nomination documents to the Chair of the Nominating Committee, all of which should reach the London Secretariat office, as soon as possible and prior to the deadlines in the text above.

Electronic format is requested. •